Foldink Corp
A biotechnology startup that develops modular 3D bioprinters and customizable bioinks to democratize tissue engineering and regenerative medicine research.
- CEO / Founder
- Emmanuel Ghandilyan
- Team Size
- 11-50
- Stage
- Active
- Total Funding
- $200K
- Latest Round
- Seed
- Key Investors
- FAST (Foundation for Armenian Science and Technology); Ventures Thrive (EU); Ministry of High-Tech Industry of Armenia; Gevork Sarkisyan (strategic investor and board member); Tigran Oganesov (strategic advisor and investor)
Technology & Products
Key Products
Modular 3D Bioprinters (Syringe-based microextrusion systems), Customizable Bioinks (GelMA, Alginate-based, and freeze-dried hydrogels), X-TRUDR4™ Printheads, Bioprinting Accessories (LAP and Irgacure Photoinitiators), Custom Tissue Engineering and Scaffold Fabrication Services
Technological Advantage
Proprietary syringe-based microextrusion technology optimized for high cell viability and precision; specialized bioink formulations that support diverse cell types and tissue models.
Differentiation
Value Proposition
Lowering the cost and technical barriers of 3D bioprinting through modular, affordable hardware and high-performance biomaterials, making advanced tissue engineering accessible to every laboratory.
How They Differentiate
Foldink differentiates through a modular 'build-your-own' bioprinter approach and high-performance bioinks that eliminate batch-to-batch variability. Their value proposition centers on a superior quality-to-price ratio, making advanced tissue engineering accessible to smaller research labs that are priced out by high-end competitors.
Market & Competition
Target Customers
Biomedical researchers, academic institutions, pharmaceutical R&D departments, and biotechnological research centers.
Industry Verticals
Biotechnology, Healthcare, Pharmaceuticals, Regenerative Medicine, Cancer Research
Competitors
CELLINK (BICO), Allevi (3D Systems), Aspect Biosystems, RegenHU
Growth & Milestones
Growth Metrics
Reported first commercial sales in 2022; expanded from a university research project to a commercial entity with international distribution of bioinks and modular printheads.
Major Milestones
Founded in 2018 as a research project at Yerevan State Medical University, Incorporated as a full-fledged company in 2019, Winner of the STEP (Science and Technology Entrepreneurship Program) competition in 2021, Achieved first commercial sales of bioprinting products in 2022, Selected for the Ventures Thrive EU deep-tech acceleration program in 2023, Established Foldink Corp in Frisco, Texas to manage North American operations
Notable Customers
Yerevan State Medical University (YSMU), Institute of Molecular Biology of NAS RA, Various European research laboratories